

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 July 2001 (26.07.2001)

PCT

(10) International Publication Number
WO 01/53457 A3

(51) International Patent Classification⁷: C07K 5/00,
14/00, A61K 39/00, 43/00

(74) Agents: ANTLER, Adriane, M. et al.; Pennie & Edmonds
LLP, 1155 Avenue of the Americas, New York, NY 10036
(US).

(21) International Application Number: PCT/US01/01665

(22) International Filing Date: 18 January 2001 (18.01.2001)

(81) Designated States (*national*): AU, CA, JP.

(25) Filing Language: English

(84) Designated States (*regional*): European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE, TR).

(26) Publication Language: English

(30) Priority Data:
09/489,219 21 January 2000 (21.01.2000) US

Published:
— with international search report

(71) Applicant: UNIVERSITY OF CONNECTICUT
HEALTH CENTER [US/US]; 263 Farmington Avenue,
Farmington, CT 06030 (US).

(88) Date of publication of the international search report:
18 April 2002

(72) Inventor: SRIVASTAVA, Pramod, K.; 70 Pheasant Run,
Avon, CT 06001 (US).

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*



WO 01/53457 A3

(54) Title: VACCINES AGAINST NEURODEGENERATIVE DISORDERS

(57) Abstract: The present invention relates to pharmaceutical compositions comprising antigenic molecules for use as vaccines for the treatment and prevention of neurodegenerative disorders and diseases, such as Alzheimer's Disease. The invention further relates to methods for the use of such pharmaceutical compositions as immunotherapeutic agents for treating and protecting against such neurodegenerative disorders and disease.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/01665

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07K 5/00, 14/00; A61K 39/00, 43/00

US CL : 530/300, 350; 424/1.11, 184.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/300, 350; 424/1.11, 184.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields
searched
Author search

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Medline, WEST

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Cederbaum. J.M. A Phase I Study of Recombinant Human Ciliary	1-3, 5, 16, 26,
--	Neurotrophic Factor (rHCNTP) in Patients with Amyotrophic Lateral	28,
Y	Sclerosis. Clinical Neuropharmacology. 1995. Vol. 18. No. 6.	---
	pages 515-532, especially abstract.	1-33
Y	Sanan. D.A. Apolipoprotein E Associates with Beta Amyloid Peptide	1-33
	of Alzheimer's Disease to Form Novel Monofibrils. J. Clin. Invest.	
	August 1994 Vol. 94. pages 860-869	
Y	LaDu M.J. Purification of Apolipoprotein E Attenuates Isoform	1-33
	Specific Binding to Beta Amyloid. J. of Biol. Chem. April 1995.	
	Vol. 270. No. 16. pages 9039-42	

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"A" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

19 JUNE 2001

Date of mailing of the international search report

27 JUL 2001

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer:

SHARON L. TURNER

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/01665

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	McGeer. P.L. Apolipoprotein E4(ApoE4) but not ApoE3 or ApoE2 potentiates Beta-amyloid protein activation of complement in vitro. Brain Research. 1997. Vol. 749. pages 135-138.	1-33
X	AL-SABBAGH. A.M. Decreased CNS Inflammation and Absence of Clinical Exacerbation of Disease After Six Months Oral Administration of Bovine Myelin in Diseased SJL/J Mice with Chronic Relapsing Experimental Autoimmune Encephalomyelitis. J. of Neuroscience Research. 1996. Vol. 45. pages 424-429	1-3, 5, 16, 26, 28 -----
Y		1-33
X	US 5,739,109 A (GALPIN ET AL) 14 April 1998 (14-04-95), see entire document, especially claims.	1-3, 5, 16, 26, 28 -----
Y		1-33
X	US 5,811,243 (STRITTMATTER ET AL) 22 September 1998 (22-09-98) columns 2-3.	1-6, 16-20, 26, 28 -----
Y		1-33
Y	US 5,780,587 A (POTTER) 14 July 1998 (14-07-98), columns 2-3.	1-33